프레스티지바이오로직스
Financials
Valuation Metrics
프레스티지바이오로직스's Market Cap is ₩882B. At end of 2025 it was ₩2360B. Ranked #1285 of 2,410 in KR market (top 53%), #704 of 1,631 on KOSDAQ (top 43%), #143 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 88.17B KRW | KR#1,285/2,410 Sec#143/231 |
| Revenue | 26.67B KRW | KR#2,069/2,410 Sec#145/231 |
| Net Income | -51.22B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 266.56B KRW | KR#1,111/2,410 Sec#78/231 |
| Net Assets | 90.46B KRW | KR#1,490/2,410 Sec#118/231 |
| Employees | 211 | KR#1,060/2,410 Sec#88/231 |
| Value | ||
| P/B | 0.97x | KR#1,538/2,410 Sec#97/231 |
| P/S | 3.31x | KR#2,046/2,410 Sec#129/231 |
| FCF Yield | 1.03% | KR#1,140/2,410 Sec#84/231 |
| Profitability | ||
| ROE | -56.62% | KR#2,286/2,410 Sec#201/231 |
| ROA | -19.22% | KR#2,227/2,410 Sec#173/231 |
| Op. Margin | -184.89% | KR#2,320/2,410 Sec#184/231 |
| Revenue Growth | 112.75% | KR#73/2,410 Sec#13/231 |
| Financial Health | ||
| Debt Ratio | 194.68% | KR#2,084/2,410 Sec#217/231 |
| Total Debt | 153.32B KRW | KR#597/2,410 Sec#34/231 |
| FCF | 910.9M KRW | KR#1,152/2,410 Sec#88/231 |
| Cash | 6.94B KRW | KR#1,878/2,410 Sec#167/231 |
| Current Ratio | 0.29x | KR#2,198/2,410 Sec#214/231 |
| Performance | ||
| 1Y Return | -62.39% | KR#2,184/2,410 Sec#209/231 |
| 1M Return | -20.92% | KR#1,667/2,410 Sec#166/231 |
| From 52W High | -70.55% | KR#2,051/2,410 Sec#172/231 |
| 1Y MDD | -69.92% | KR#1,943/2,410 Sec#165/231 |
| Trading | ||
| Volume | 527,946 shares | KR#449/2,410 Sec#50/231 |
| Trading Value | 572.7M KRW | KR#1,237/2,410 Sec#129/231 |
| Foreign Own. | 41.63% | KR#55/2,410 Sec#4/231 |
| Per Share | ||
| EPS | -659 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,163 KRW | KR#2,267/2,410 Sec#204/231 |
Company Info
Prestige Biologics, established in 2015 and listed on KOSDAQ in 2021, specializes as a contract manufacturing organization for biopharmaceuticals. The company conducts CDEMO business, providing customized contract manufacturing services for advanced biopharmaceuticals with a 6,000L production facility at its first plant. Its second campus features the ALITA platform, integrating a Smart Factory platform with diverse production methods to enable versatile product manufacturing. Prestige Biologics is headquartered in Cheongju-si, Chungcheongbuk-do.